Mitochondrial & longevity research compounds
SS-31 (Elamipretide)
Also known as elamipretide · Bendavia · MTP-131 · Forzinity
A mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane — approved in the US in 2025 for Barth syndrome.
In 60 seconds
Accelerated US approval (September 2025) to improve muscle strength in Barth syndrome; further trials in other mitochondrial disorders. Clinical programmes report injection-site reactions as the most common effect.
- Summarises the September 2025 US accelerated approval of elamipretide for muscle strength in Barth syndrome.
- Reviews elamipretide’s structure, cardiolipin-binding mechanism and research applications.
- In an ischaemic kidney model, SS-31 preserved cristae and speeded ATP recovery by interacting with cardiolipin.
Mechanism
SS-31 concentrates in the inner mitochondrial membrane and binds cardiolipin, the lipid that holds the electron-transport chain together. This is reported to stabilise cristae structure and restore ATP production in injured mitochondria.
Research status
Accelerated US approval (September 2025) to improve muscle strength in Barth syndrome; further trials in other mitochondrial disorders.
Key studies
Summarises the September 2025 US accelerated approval of elamipretide for muscle strength in Barth syndrome.
Elamipretide: First Approval — Drugs, 2026 · PMID 41335372
Reviews elamipretide’s structure, cardiolipin-binding mechanism and research applications.
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential — Int J Mol Sci, 2025 · PMID 39940712
In an ischaemic kidney model, SS-31 preserved cristae and speeded ATP recovery by interacting with cardiolipin.
The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin — J Am Soc Nephrol, 2013 · PMID 23813215
Safety signals in the literature
Clinical programmes report injection-site reactions as the most common effect.
Legal status (South Africa)
Research compounds; not registered medicines for human use in South Africa unless stated otherwise.
Related compounds we stock
Now in the catalogue
SS-31 (Elamipretide) is now in our catalogue as a research vial. Pre-orders are 10% off until the 15 October delivery lands.
Comparisons
Questions
What is SS-31 (Elamipretide)?
A mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane — approved in the US in 2025 for Barth syndrome. SS-31 concentrates in the inner mitochondrial membrane and binds cardiolipin, the lipid that holds the electron-transport chain together. This is reported to stabilise cristae structure and restore ATP production in injured mitochondria.
What is the research status of SS-31 (Elamipretide)?
Accelerated US approval (September 2025) to improve muscle strength in Barth syndrome; further trials in other mitochondrial disorders.
What safety signals are reported for SS-31 (Elamipretide)?
Clinical programmes report injection-site reactions as the most common effect.
Does Living Water Labs stock SS-31 (Elamipretide)?
Not at present. SS-31 (Elamipretide) is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Research compounds; not registered medicines for human use in South Africa unless stated otherwise.
More in Mitochondrial & longevity
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
